Publications by authors named "Airi Poder"

Claim this Profile
C
Comparative efficacy and safety of biosimilar Bmab 1200 versus reference ustekinumab in moderate-to-severe plaque psoriasis: 52-week findings from the Phase 3 STELLAR-2 trial.
Jacek C Szepietowski, Adam Reich, Steven R Feldman, Grazyna Pulka, Lally Mekokishvili, Airi Poder

Expert Opin Biol Ther· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Herpes zoster recurrence, and safety and immunogenicity of the recombinant zoster vaccine in adults aged ≥50 years with a history of herpes zoster: A phase 3, randomized controlled trial.
Bisi Jegede, Yingjun Zhou, Helen Hawksworth, David S C Hui, Nathali Montenegro Guerra

J Infect· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of the ustekinumab biosimilar, Bmab 1200, versus reference ustekinumab in moderate-to-severe plaque psoriasis: 28‑week results of the randomized, double-blind, Phase 3 STELLAR-2 study.
Jacek C Szepietowski, Adam Reich, Steven R Feldman, Grazyna Pulka, Lally Mekokishvili, Airi Poder

Expert Opin Biol Ther· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final analysis of the ZOE-LTFU trial to 11 years post-vaccination: efficacy of the adjuvanted recombinant zoster vaccine against herpes zoster and related complications.
Ana Strezova, Javier Díez Domingo, Anthony L Cunningham, Takashi Eto, Charles Andrews

EClinicalMedicine· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1)" [Vaccine 41 (2023) 3387-3398].
Federico Martinon-Torres, Jacek Wysocki, Leszek Szenborn, Alfonso Carmona-Martinez, Airi Poder

Vaccine· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of candidate biosimilar CT-P41 versus reference denosumab: a double-blind, randomized, active-controlled, Phase 3 trial in postmenopausal women with osteoporosis.
Jean-Yves Reginster, Edward Czerwinski, Krzysztof Wilk, Przemysław Borowy, Anna Strzelecka

Osteoporos Int· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of the non-typable - (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: Results from a randomized, phase 2a, non-inferiority trial.
Ilaria Galgani, Airi Põder, Rain Jõgi, Veli-Jukka Anttila, Stefano Milleri

Hum Vaccin Immunother· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50-64 Years of Age.
Airi Poder, Janine Oberije, Jay Meyer, Peter Heymer, Deborah Molrine

Vaccines (Basel)· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1).
Federico Martinon-Torres, Jacek Wysocki, Leszek Szenborn, Alfonso Carmona-Martinez, Airi Poder

Vaccine· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Respiratory Syncytial Virus Disease Burden in Community-Dwelling and Long-Term Care Facility Older Adults in Europe and the United States: A Prospective Study.
Sílvia Narejos Pérez, Josep María Ramón Torrell, Airi Põder, Isabel Leroux-Roels, Lina Pérez-Breva

Open Forum Infect Dis· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunological non-inferiority of a new fully liquid presentation of the MenACWY-CRM vaccine to the licensed vaccine: results from a randomized, controlled, observer-blind study in adolescents and young adults.
Javier Díez-Domingo, Juan Carlos Tinoco, Airi Poder, Ener Cagri Dinleyici, Haylene Nell

Hum Vaccin Immunother· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of a Cell-Culture-Derived Quadrivalent Influenza Vaccine in Children.
Terence Nolan, Alexandre C Fortanier, Brett Leav, Airi Põder, Lulu C Bravo

N Engl J Med· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevention of influenza during mismatched seasons in older adults with an MF59-adjuvanted quadrivalent influenza vaccine: a randomised, controlled, multicentre, phase 3 efficacy study.
Jiří Beran, Humberto Reynales, Airi Poder, Charles Y Yu, Punnee Pitisuttithum

Lancet Infect Dis· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to 'Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥50 years of age: A randomized trial' [Vaccine 36 (2018) 4278-4286].
Céline Maréchal, Himal Lal, Airi Poder, Murdo Ferguson, Igwebuike Enweonye

Vaccine· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The growing and important collaboration between BASHH and IUSTI-Europe.
Rajul Patel, Jackie Sherrard, Daniel Richardson, Airi Poder

Sex Transm Infect· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥50 years of age: A randomized trial.
Céline Maréchal, Himal Lal, Airi Poder, Murdo Ferguson, Igwebuike Enweonye

Vaccine· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MenACWY-TT is immunogenic when co-administered with Tdap and AS04-HPV16/18 in girls and young women: Results from a phase III randomized trial.
Luis Rivera, Pornthep Chanthavanich, Airi Põder, P V Suryakiran, Archana Jastorff

Vaccine· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study.
Himal Lal, Airi Poder, Laura Campora, Brecht Geeraerts, Lidia Oostvogels

Vaccine· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial.
Maurizio Cutolo, Gary E Myerson, Roy M Fleischmann, Frédéric Lioté, Federico Díaz-González, Airi Poder

J Rheumatol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults.
Himal Lal, Anthony L Cunningham, Olivier Godeaux, Roman Chlibek, Javier Diez-Domingo, Airi Poder

N Engl J Med· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HIV in Europe.
Airi Põder, Madli Haldre

Clin Dermatol· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age.
Airi Poder, Pavol Simurka, Ping Li, Sumita Roy-Ghanta, David Vaughn

Vaccine· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young women.
Tiina Petäjä, Court Pedersen, Airi Poder, Gitte Strauss, Gregory Catteau

Int J Cancer· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of ID-PaGIA syphilis antibody test.
Paul Naaber, Ene Makoid, Anneli Aus, Krista Loivukene, Airi Poder

Indian J Dermatol Venereol Leprol· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant.
Court Pedersen, Tiina Petaja, Gitte Strauss, Hans C Rumke, Airi Poder

J Adolesc Health· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis